Mandate

Vinge Advises Smedvig Capital

May 14, 2008

Vinge advised London based Norwegian private equity company Smedvig Capital in connection to their investment in SelStor AB. SelStor AB, founded in 2006, will provide self-storage warehouses to private individuals and companies. Smedvig’s invests SEK 100 million (through Peder Smedvig Capital Fund IX LP) via a variety of bonds and receives, after full subscription, 45 percent of the shares. In addition Smedvig shall provide shareholder’s loans to a value of SEK 75 million. Vinge advised Smedvig on the establishment and negotiation of the subscription agreement, shareholder’s agreement and loan, employment agreements and the customary due diligence process.

Vinge’s team included partner Ulf Sällnäs joined by Hillevi Myhre, Sarah Khalil, Johan Bocander, Maria Schultzberg, Maria Doeser, Åsa Gotthardsson, Anders Frick, Johan Cederblad and Pernilla Warg.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024